Key takeaways
- Elamipretide (SS-31) has randomised trials in people: a 2021 study in 39 healthy older adults measured ATP production in a hand muscle, and trials in two patient groups used walking distance and fatigue scores as main measures and did not beat placebo.
- Elamipretide is the active ingredient of one US medicine, Forzinity, whose label covers muscle strength in adults and children with Barth syndrome weighing at least 30 kg; research-grade material labelled SS-31 is not that medicine.
- NAD+ is a coenzyme, not a peptide. A 2019 pilot study measured it in the blood and urine of 11 men, and a 2026 analysis pooling four trials of NAD+ and nicotinamide riboside found no significant difference from placebo in its main outcomes, none of them a measure of energy or fatigue, and a rise in a kidney marker with NAD+.
- No published study we found has given MOTS-c or humanin to people (PubMed and ClinicalTrials.gov, 21 November 2026); the MOTS-c studies that gave it measured treadmill running and energy expenditure in mice.
- In these studies “energy” is something measured: ATP production, walking distance, a fatigue score, treadmill time or a blood level. The fatigue scores come from trials in patients with genetic conditions, not from healthy people.
01How far has research on peptides and energy gone?
How far the published research has gone for each compound, dated 21 November 2026. Each bar shows the strongest type of study that gave the compound and measured something related to energy. A longer bar means a stronger study design, not a better result. Bar lengths show order only; they are not a score.
Elamipretide: randomised trials measured ATP production in muscle, walking distance and fatigue scores. NAD+: a pilot study measured its level in blood and urine. MOTS-c: mouse studies measured treadmill running and energy expenditure. Humanin: the human studies we found measured the body’s own levels, and none gave it to people.
Source: the studies listed in the next section; PubMed and ClinicalTrials.gov searches, 21 Nov 2026.
Is any of them approved for energy or fatigue? No. One of the four is the active ingredient of a US medicine: elamipretide, as Forzinity. Its label says it is “indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg”, under accelerated approval first granted on 19 September 2025. The label says that approval rests on an improvement in knee extensor muscle strength, an intermediate clinical endpoint, and that continued approval may depend on a confirmatory trial. That is not an approval for energy or fatigue, and research-grade material labelled SS-31 is not that medicine. FDA staff wrote in 2026 that MOTS-c is not a component of any FDA-approved drug, and Drugs@FDA lists no product containing NAD+ or humanin (searched 21 November 2026).
02What did each study measure, and in which model?
Each compound, the strongest study we found that gave it and measured something related to energy, and what that study cannot tell you. Dated 21 November 2026. Tiers follow our evidence grades; sources are at the end of the page.
| Compound | What it is | Strongest study with an energy-related measure | What was measured | Tier | What we don’t know |
|---|---|---|---|---|---|
| Elamipretide (SS-31) | A four-amino-acid peptide that binds cardiolipin, a fat in the inner membrane of mitochondria | MMPOWER-3, 2023: phase 3, randomised, double-blind, placebo-controlled; 218 adults with primary mitochondrial myopathy; 24 weeks. Also a 2021 randomised, placebo-controlled study in 39 healthy adults aged 60 to 85 | Distance walked in six minutes and a total fatigue score (2023); peak ATP production in a hand muscle (2021) | T1 | Any effect on energy in healthy people beyond one muscle measure recorded right after a single treatment |
| NAD+ | A coenzyme for the redox reactions of energy metabolism; not a peptide | Pilot study, 2019: 11 healthy men aged 30 to 55, 8 given NAD+ and 3 given saline | NAD+ and its breakdown products in blood and urine | T2 | Whether giving NAD+ changes how energetic anyone feels or performs: the pilot measured levels only, and the pooled trials described below report no energy or fatigue measure |
| MOTS-c | A 16-amino-acid peptide encoded in mitochondrial DNA | Reynolds et al., 2021: mice aged 2, 12 and 22 months, 5 to 19 per group. Lee et al., 2015: male mice on a high-fat diet, N=10 in the paper | Treadmill running time and distance (2021); body weight, insulin, energy expenditure and heat production (2015) | T3 | Any effect in people: no published study has given it to people, and the one registered trial has no results |
| Humanin | A peptide encoded in mitochondrial DNA | von Walden et al., 2021: 30 adults randomised to endurance exercise, resistance exercise or no exercise (10 each). Nobody was given humanin | The body’s own humanin and MOTS-c in blood, before and after exercise | T2 (natural levels) | Anything about giving humanin to people: we found no study that did |
One related molecule appears in the NAD+ row: nicotinamide riboside (NR), which cells convert into NAD+. It is a different molecule, and a trial of NR is not a trial of NAD+.
03What are these compounds, and where was each one tested?
The link between these compounds and “energy” is cell biology. Mitochondria are the compartments that produce most of a cell’s energy. Elamipretide binds a membrane inside them, MOTS-c and humanin are encoded in their DNA, and NAD+ is a coenzyme in the redox reactions of energy metabolism. None of that is a statement about how a person feels.
Elamipretide (SS-31)
Binds cardiolipin in the inner membrane of mitochondria, according to its US label. Tested against placebo in people.
NAD+
A coenzyme for the redox reactions of energy metabolism, not a peptide. A pilot study measured it in blood and urine.
MOTS-c
A 16-amino-acid peptide encoded in mitochondrial DNA. The studies that gave it used mice and cells.
More on each: SS-31 (elamipretide), NAD+ and MOTS-c.
04What have studies in people measured?
Two of the four have been given to people in published studies: elamipretide and NAD+. We report what each study measured and whether it met its main goal.
Elamipretide: ATP production in older adults (T1, small, n=39). A randomised, double-blind, placebo-controlled study gave a single treatment to 39 healthy adults aged 60 to 85, enrolled for poorly functioning mitochondria, and measured peak ATP production in a hand muscle by magnetic resonance spectroscopy. Right after treatment the change versus placebo was borderline (p=0.055 for the absolute change, p=0.045 for the percentage change). On day 7 there was no difference, and resistance to fatigue in the same muscle did not change. The developer, Stealth BioTherapeutics, funded the study.
Elamipretide: walking distance and fatigue in patients (T1). The phase 3 MMPOWER-3 trial randomised 218 adults with genetically confirmed primary mitochondrial myopathy to elamipretide or placebo for 24 weeks. Its primary endpoints were the distance walked in six minutes and a total fatigue score; it met neither. In the crossover trial on the US label, 12 males aged 12 to 35 with Barth syndrome received elamipretide and placebo in a random sequence. The primary endpoints were again a six-minute walk and a fatigue score, and the label says the medicine “was not superior to placebo” on them.
NAD+: levels in blood and urine (T2, n=11). A 2019 pilot study gave NAD+ to 8 healthy men aged 30 to 55 and saline to 3, and measured NAD+ and its breakdown products in their blood and urine. It measured levels, not how anyone felt or performed. It was funded jointly by a company and a research institute; one author is a director of that company and medical director of the clinic where the study was run.
NAD+ and a precursor, pooled (T1, small trials). A systematic review and meta-analysis published on 17 November 2026 pooled four randomised, placebo-controlled trials in 387 adults with symptomatic heart failure who were on standard treatment. The trials tested NAD+ or nicotinamide riboside (NR). The primary outcomes were heart-failure hospital admissions, deaths from any cause and left ventricular ejection fraction, the share of blood the heart pumps out with each beat. None differed significantly from placebo. Nor did measures of heart size and strain, NT-proBNP (a blood marker of heart strain) or ALT (a liver marker). Serum creatinine, a kidney marker, rose with NAD+ (two trials, 209 people). The authors wrote that the treatments “appeared generally well tolerated in the short term”, but that the creatinine rise “warrants further evaluation”. The abstract reports no measure of energy or fatigue.
A precursor on its own: NR (T1, small, n=24). A 2018 randomised, placebo-controlled crossover trial in healthy adults aged 55 to 79, which 24 completed, measured NAD+ in blood cells after six weeks of NR and after six weeks of placebo. The level was higher after NR. In the same trial, energy expenditure, VO2max and treadmill time to exhaustion did not differ from placebo. A higher level in blood cells is a lab value, not an outcome.
What a 2026 systematic review concluded. A review of human and rodent studies of NAD+ and its precursors, covering January 2010 to October 2025, included 33 human studies, 28 of them randomised. In people, it found that NR and NMN by mouth changed NAD-related measures in blood or blood cells, while effects on functional and other health-related outcomes were “heterogeneous and often null or endpoint-specific”. One of its two authors declared owning a company that provides administrative services to an aesthetics clinic, which the declaration says offers no NAD+ products or treatments.
We describe designs and measures, and report null results in full. Why we never state amounts: our policy.
05What have MOTS-c and humanin studies measured, and in which models?
The studies that gave MOTS-c used mice and cells. We describe the models and what was measured, not the authors’ findings. Animal results are not evidence of an effect in people.
MOTS-c: energy expenditure in mice (T3). The 2015 paper that described MOTS-c, a 16-amino-acid peptide encoded in mitochondrial DNA, gave it to male mice on a high-fat diet (N=10 in the paper). It recorded body weight, food intake, glucose and insulin, and measured energy expenditure, heat production and activity.
MOTS-c: treadmill running in mice (T3). In 2021 the same research group measured treadmill running time and distance in mice aged 2, 12 and 22 months, in groups of 5 to 19, and grip strength, stride length and a 60-second walking test in old mice. Two of the authors declared consulting roles and shares in CohBar, Inc.
MOTS-c in people: natural levels only (T2). In the same 2021 paper, 10 young men cycled and researchers measured the MOTS-c their own bodies made, in muscle and blood. A 2021 study in Sweden randomised 30 adults to endurance exercise, resistance exercise or no exercise (10 each) and measured blood levels of MOTS-c and humanin; its authors reported that those levels were “not correlated to fitness outcomes”. Neither study gave MOTS-c to anyone.
The registered trial. No published study has given MOTS-c to people (PubMed and ClinicalTrials.gov, 21 November 2026). One trial is registered: NCT07505745, a phase 2a, randomised, placebo-controlled trial planned for 120 adults with prediabetes and overweight or obesity. Its primary outcomes are an insulin-sensitivity index and adverse events, not an energy measure. It is recruiting and has posted no results.
What regulators concluded. Reviewing MOTS-c in 2026, FDA staff found “a lack of evidence to evaluate the effectiveness” for its nominated uses, because the studies were “limited to in-vitro and in-vivo rodent models”, and wrote that “potential safety risks associated with the use of MOTS-c in humans are unknown”. FDA’s compounding page says MOTS-c products “may pose significant risk for immunogenicity for certain routes of administration”. HHS read the record differently: its 2026 policy appendix says “the available safety evidence points in one direction”, citing a trial of an unnamed MOTS-c analogue, a different molecule, that “reported no serious adverse events”. In sport, WADA names MOTS-c in class S4.4.1, metabolic modulators, prohibited at all times in the 2026 and 2027 Lists. More: the MOTS-c guide and MOTS-c claims and the evidence.
Humanin. Humanin is another peptide encoded in mitochondrial DNA. None of the eight humanin records that PubMed indexes as clinical trials gave it to people, and ClinicalTrials.gov lists no trial that gives it (both searched 21 November 2026). In the Swedish exercise study above, blood humanin rose after endurance exercise but not after resistance exercise. That shows when a natural level changes, not what giving humanin would do.
06What does “energy” mean in these studies?
In everyday speech, energy means how alert or how tired you feel. In these studies it is one of five things that can be measured.
ATP is the molecule that carries energy inside cells. One elamipretide study measured the peak rate at which a hand muscle made it, in 39 older adults.
A test of exercise capacity. It was a main measure in the two elamipretide trials in patients.
A questionnaire. The scores on this page come from patients with primary mitochondrial myopathy or Barth syndrome, not from healthy people.
How long and how far a mouse runs, and how much energy its body uses. These are the MOTS-c measures.
NAD+ in blood, urine or blood cells, or the body’s own MOTS-c and humanin. A level is a lab value.
None of the five is the same as feeling more energetic. Only the fatigue scores ask people how they feel.
07What has not been shown about peptides and energy?
An effect on energy in healthy people
The elamipretide study in healthy older adults measured ATP production in one hand muscle after a single treatment. By day 7 there was no difference from placebo.
That mouse results carry over to people
No published study has given MOTS-c or humanin to people (PubMed and ClinicalTrials.gov, 21 Nov 2026). The registered MOTS-c trial has no results.
That a higher NAD+ level means more energy
In the 2018 trial of the precursor NR, NAD+ in blood cells was higher after NR, while energy expenditure, VO2max and treadmill time did not differ from placebo.
Long-term effects
The pooled trials of NAD+ and NR found a rise in a kidney marker with NAD+ that their authors said “warrants further evaluation”. FDA staff call the risks of MOTS-c in people unknown.
How these tiers are assigned: evidence grades. Related areas: MOTS-c research and longevity research.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not medical or legal advice.